P3284 Exploratory Exposure-response (E-R) Analysis of ESK-001, an Allosteric Oral TYK2 Inhibitor, in Patients with Plaque Psoriasis

Sibel Ucpinar¹, David H Salinger², Grace Ma¹, Roman G. Rubio¹, Jeffrey Douglas¹, Claire L. Langrish¹, Philip A. Nunn¹, ¹Alumis Inc., South San Francisco, CA, US; ²Certara Inc., Radnor, PA, US

sucpinar@alumis.com

Disclosures: Commercial support was provided by Alumis Inc. All authors have no other relationships or conflicts of interest

European Academy of Dermatology & Venereology Congress, September 25-28, 2024

Tyrosine Kinase 2 (TYK2) is central to key pathways in many immune-mediated diseases


- TYK2 mediates signaling from key proinflammatory cytokines, including IL-23, IL-12, and type I IFN, through STAT phosphorylation.
- > Human TYK2 loss-of-function genetic variants protect from immune-mediated diseases, including plaque psoriasis (PsO).¹
- > TYK2 is an established therapeutic target, with TYK2 inhibitors being recently approved for PsO.²

IL-23, IL-12, IFN **TYK2** JAK1/2 STAT NUCLEUS MMMMM Inflammatory Mediators IL-23/12 pathways **IFN pathways** IFN driven diseases IL-23/12 driven diseases

Background

ESK-001 is an oral, highly selective allosteric inhibitor of TYK2 being developed for immunemediated diseases, including plaque PsO

- Potent and intrinsically selective for TYK2, without observed JAK-related pharmacology.
- > Allosterically inhibits TYK2, with maximal target inhibition maintained over 24 hours with 40 mg BID dose (both IC50 and IC90).



> To develop a **population pharmacokinetic (popPK) model** to characterize the ESK-001 PK, using data from three Phase I studies and one Phase II study (STRIDE study followed by an open-label extension [OLE] study).

Objectives

To perform an exploratory exposure-response (E-R) analysis to understand the relationship between ESK-001 exposure and efficacy endpoints: skin improvements (PASI), severity reduction (sPGA), and change in the disease's body surface area (%BSA) through Week 12 (STRIDE study) and through Week 40 (OLE study) to inform Phase III dose selection.

Study Design

E-R Analysis


Phase II STRIDE Study (N=228*)

OLE Study (N=165*)

- **STRIDE study** = a 12-week randomized, double-blinded, placebo-controlled Phase II study of ESK-001 in adults with moderate-to-severe plaque PsO (NCT05600036).
 - Subjects with plaque PsO were randomized to receive one of the 5 doses of ESK-001 or placebo, given orally for 12 weeks.
 - Study design and eligibility criteria were presented previously.³
 - *Efficacy endpoints were assessed at baseline and Week 2, 4, 8, and 12.*
- **OLE study** = an ongoing open-label extension study with ESK-001 (NCT05739435).
- This study enrolled 95% of eligible subjects who completed the STRIDE study.
- *Efficacy and safety endpoints were assessed at multiple time points.*
- The 24-hour average concentration of ESK-001 (Cavg) was used to assess effects on efficacy endpoints.

Methods

- Efficacy endpoints were **PASI**, sPGA, %BSA change (% of subjects with <1, <3, and <10% BSA involved with PsO).
- Exploratory graphs visualized the effects of exposure and time on each efficacy endpoint.




Results

Development of PopPK model

- Data from 121 healthy subjects and 185 subjects with PsO.
- Developed and verified using data from three Phase I studies and one Phase II study:
 - Phase I studies: single- (SAD) and multipleascending dose (MAD) (ACTRN12621000011886)⁴, *multiple dose (MD) (NCT05431634)*⁴, *relative* bioavailability and food effect study (NTC05330858).
 - *Phase II study: STRIDE study.*
- > The collected data best fit a **two-compartment model** with first-order absorption and linear elimination.
- > Absorption was represented as a series of five transit compartments with relatively rapid transitions.
- The model accurately reflected the observed data, showing both the overall trend and the differences

The PopPK modeling diagram



Ktr = *transition rate constant; KA* = *absorption rate constant; Q* = intercompartmental clearance; *MTT* = mean transit *time, V* = *volume of distribution, CL* = *clearance*

PopPK model was used derive the to


STRIDE study.

24-hour Cavg values for each subject in the


E-R analysis revealed a strong, positive relationship between exposure and efficacy endpoints

- > The exploratory E-R analyses demonstrated an exposure-dependent increase in key efficacy endpoints PASI-75, sPGA 0/1, and %BSA change responses.
- > The PASI, sPGA, and %BSA scores continued to improve during the OLE compared to Week 12 STRIDE results, indicating that longer treatment periods at the highest dose led to better responses with the same drug exposure.
- The maximal response was observed at the highest dose of 40 mg BID.

STRIDE study







between individuals.

Cavg as matrix to assess the exploratory E-R analysis

- > Cavg of ESK-001 was categorized into four exposure groups or **bins** (Bin 1 = placebo, Bin 2-4 = tertiles of exposure from low to high; number of subjects is about equal for each bin).
- STRIDE Week 12 Cavg probability distribution by exposure bins showed that 40 mg BID had substantially higher exposures overall and thus, would be expected to have the strongest efficacy.

Efficacy


STRIDE study

- Primary and all secondary endpoints (PASI, sPGA, %BSA) were met at 40 mg BID dose.
- Clear dose-dependent effect was observed.
- > Maximal TYK2 inhibition was achieved at the highest dose (40 mg BID) at Week 12.

			•	•				
% Patients	100							
achieving	100-	STRIDE	Washout	Open Label Extension	89.2	90.3	PASI-75	90.9
PASI-75	(%)	Placebo		40 mg BID				


STRIDE Week 12 Cavg probability


distribution by bins




> Continued ESK-001 exposure achieved substantial increases in efficacy responses.


Cavg Bin (ng/mL)











0/1